Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Novavax clinical trials
The registry lists 48 studies whose lead sponsor is Novavax or one of 1 company grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Novavax.
- Novavax47 studiesSame company
Something wrong?
- 1 study →
Focus areas
Conditions Novavax leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 48 of 48.
- Efficacy and Safety of NVX-CoV2705TerminatedNCT07086222Phase 4
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination VaccineCompletedNCT06291857Phase 3
- Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United StatesCompletedNCT06633835Phase 4
- Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 YearsCompletedNCT05468736Phase 2/3
- Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in AdultsCompletedNCT05463068Phase 3
- A Strain Change Study for SARS-CoV-2 rS VaccinesCompletedNCT06409663Phase 3
- Phase 3 Adolescent Study for SARS-CoV-2 rS Variant VaccinesCompletedNCT05973006Phase 3
- Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA VaccinesCompletedNCT05875701Phase 3
- A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United KingdomCompletedNCT04583995Phase 3
- A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal ImmunizationCompletedNCT02624947Phase 3
- Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination VaccineCompletedNCT04961541Phase 1/2
- Lot Consistency Study of COVID-19 and Influenza Combination VaccineWithdrawnNCT06482359Phase 2/3
- Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza VaccineWithdrawnNCT06485752Phase 2/3
- Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS VaccinesCompletedNCT05925127Phase 2/3
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination VaccineCompletedNCT05519839Phase 2
- A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.CompletedNCT05975060Phase 2/3
- Phase 3 Boosting Study for the SARS-CoV-2 rS Variant VaccinesCompletedNCT05372588Phase 3
- A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2CompletedNCT04611802Phase 3
- Phase 3 Pivotal Trial of NanoFlu™ in Older AdultsCompletedNCT04120194Phase 3
- Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M AdjuvantCompletedNCT04368988Phase 1/2
- A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)CompletedNCT05112848Phase 2
- Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)CompletedNCT03293498Phase 1/2
- Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older AdultsTerminatedNCT03658629Phase 2
- A Study to Evaluate the Efficacy of an RSV F Vaccine in Older AdultsCompletedNCT02608502Phase 3
- Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in AdultsWithdrawnNCT05029856Phase 1/2
- RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.CompletedNCT02247726Phase 2
- Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.CompletedNCT02593071Phase 2
- Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly AdultsCompletedNCT02266628Phase 2
- A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African AdultsCompletedNCT04533399Phase 2
- Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older AdultsCompletedNCT03026348Phase 2
- Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy SubjectsCompletedNCT02370589Phase 1
- A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ AdjuvantCompletedNCT02078674Phase 1/2
- Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young AdultsCompletedNCT02307851Phase 2
- RSV F Dose-Ranging Study in WomenCompletedNCT01960686Phase 2
- A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of AgeCompletedNCT02296463Phase 1
- A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1CompletedNCT01897701Phase 1
- RSV-F Vaccine Dose Ranging Study in Young WomenCompletedNCT01704365Phase 2
- RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the ElderlyCompletedNCT01709019Phase 1
- A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1CompletedNCT01594320Phase 1
- A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2CompletedNCT01596725Phase 1
- A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young AdultsCompletedNCT01561768Phase 2
- Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy AdultsCompletedNCT00754455Phase 2
- Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)CompletedNCT00903552Phase 2
- Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older AdultsCompletedNCT01014806Phase 2
- Safety, Reactogenicity and Immunogenicity of an H5N1 VLPCompletedNCT00519389Phase 1/2
- Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) VaccineCompletedNCT01072799Phase 2
- Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle VaccineCompletedNCT01290419Phase 1
- Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly VolunteersStatus unknownNCT01444482Phase 1
Sponsor listed in the registry: Isconova AB · First submitted before Isconova AB became part of Novavax